Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spa
- PDF / 541,989 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 26 Downloads / 190 Views
RESEARCH ARTICLE
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain A. Rodríguez‑Lescure1 · F. A. de la Peña2 · E. Aranda3 · A. Calvo4 · E. Felip5 · P. Garrido6 · R. Vera7 Received: 2 April 2020 / Accepted: 28 April 2020 © The Author(s) 2020
Abstract Purpose The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. Methods A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. Results Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues. Keywords Oncology · Drug · Biomarker · Equity · Access · Barriers · Spain
Introduction Cancer is a primary health problem due to its high incidence, prevalence, and mortality rates. Worldwide in 2018, 18.1 million new cases cancer were identified and a total of 9.5 million cancer-associated deaths were registered. In the next 20 years, the incidence of cancer is predicted to increase by
approximately 64% and to reach an estimate of 29.5 million new cases in 2040 [1]. In Spain, an estimated total of 227,234 new cancer cases were detected in 2019 [1], being the second leading cause of mortality in the overall population following cardiovascular disease, and the leading overall cause in the male population [2].
* A. Rodríguez‑Lescure [email protected]
2
Haematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
F. A. de la Peña [email protected]
3
Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain
4
Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
5
Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain
6
Medical Oncology Department, Hospital Universitario Ramón Y Cajal, Madrid, Spain
7
Medical Oncology Department, Complejo Hospitalario de Navarra, Navarrabiomed, IdISNA, Pamplona, Spain
E. Aranda [email protected] A. Calvo [email protected] E. Felip [email protected] P. Garrido [email protected] R. Vera [email protected] 1
Medical Oncology Department, Hospital General Universitario de El
Data Loading...
